blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2917244

EP2917244 - APROTININ-DERIVED POLYPEPTIDE-ANTIBODY CONJUGATES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  12.11.2021
Database last updated on 03.09.2024
FormerThe patent has been granted
Status updated on  04.12.2020
FormerGrant of patent is intended
Status updated on  28.05.2020
FormerExamination is in progress
Status updated on  18.01.2019
Most recent event   Tooltip27.04.2024Lapse of the patent in a contracting state
New state(s): MK		published on 29.05.2024  [2024/22]
Applicant(s)For all designated states
Angiochem Inc.
201 President Kennedy Avenue
Suite PK-2880
Montréal, QC H2X 3Y7 / CA
[2015/40]
Former [2015/38]For all designated states
Angiochem Inc.
201 President Kennedy Avenue Suite PK-R220
Montréal, QC H2X 3Y7 / CA
Inventor(s)01 / TRIPATHY, Sasmita
4451 King Street
Pierrefonds Québec H9H 2G2 / CA
02 / DEMEULE, Michel
343 Preston Drive
Beaconsfield Québec H9W 1Z2 / CA
03 / CURRIE, Jean-Christophe
2 Rue Lord
Repentigny Québec J6A 6C9 / CA
 [2015/38]
Representative(s)Lahrtz, Fritz, et al
Patentanwälte
Isenbruck Bösl Hörschler PartG mbB
Seckenheimer Landstr. 4
68163 Mannheim / DE
[2021/01]
Former [2015/38]Lahrtz, Fritz
Isenbruck Bösl Hörschler LLP Patentanwälte Prinzregentenstrasse 68
81675 München / DE
Application number, filing date13853308.812.11.2013
[2015/38]
WO2013CA50863
Priority number, dateUS201261725365P12.11.2012         Original published format: US 201261725365 P
[2015/38]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014071531
Date:15.05.2014
Language:EN
[2014/20]
Type: A1 Application with search report 
No.:EP2917244
Date:16.09.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 15.05.2014 takes the place of the publication of the European patent application.
[2015/38]
Type: B1 Patent specification 
No.:EP2917244
Date:06.01.2021
Language:EN
[2021/01]
Search report(s)International search report - published on:CA15.05.2014
(Supplementary) European search report - dispatched on:EP16.06.2016
ClassificationIPC:C07K19/00, A61K47/68, A61P35/00, A61P35/04, C07K14/81, C07K16/28
[2020/25]
CPC:
A61K38/57 (EP,US); A61K47/6811 (EP,US); A61K47/6843 (EP,US);
A61K47/6849 (EP,US); A61K47/6855 (EP,US); A61K47/6889 (EP,US);
A61P25/00 (EP); A61P35/00 (EP); A61P35/04 (EP);
C07K14/8117 (EP,US); C07K2319/00 (EP,US) (-)
Former IPC [2015/38]C07K19/00, A61K47/48, A61P35/00, A61P35/04, C07K14/81, C07K16/28
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/38]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:AUS APROTININ GEWONNENE ANTIKÖRPERKONJUGATE[2015/38]
English:APROTININ-DERIVED POLYPEPTIDE-ANTIBODY CONJUGATES[2015/38]
French:CONJUGUÉS POLYPEPTIDE DÉRIVÉ D'APROTININE-ANTICORPS[2015/38]
Entry into regional phase28.05.2015National basic fee paid 
28.05.2015Search fee paid 
28.05.2015Designation fee(s) paid 
28.05.2015Examination fee paid 
Examination procedure28.05.2015Examination requested  [2015/38]
11.01.2017Amendment by applicant (claims and/or description)
22.01.2019Despatch of a communication from the examining division (Time limit: M06)
31.07.2019Reply to a communication from the examining division
29.05.2020Communication of intention to grant the patent
07.10.2020Fee for grant paid
07.10.2020Fee for publishing/printing paid
07.10.2020Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  22.01.2019
Opposition(s)07.10.2021No opposition filed within time limit [2021/50]
Fees paidRenewal fee
30.11.2015Renewal fee patent year 03
28.11.2016Renewal fee patent year 04
27.11.2017Renewal fee patent year 05
27.11.2018Renewal fee patent year 06
27.11.2019Renewal fee patent year 07
27.11.2020Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU12.11.2013
AL06.01.2021
AT06.01.2021
CY06.01.2021
CZ06.01.2021
EE06.01.2021
FI06.01.2021
HR06.01.2021
LT06.01.2021
LV06.01.2021
MC06.01.2021
MK06.01.2021
PL06.01.2021
RO06.01.2021
RS06.01.2021
SI06.01.2021
SK06.01.2021
SM06.01.2021
BG06.04.2021
NO06.04.2021
GR07.04.2021
IS06.05.2021
PT06.05.2021
[2024/22]
Former [2023/30]HU12.11.2013
AL06.01.2021
AT06.01.2021
CY06.01.2021
CZ06.01.2021
EE06.01.2021
FI06.01.2021
HR06.01.2021
LT06.01.2021
LV06.01.2021
MC06.01.2021
PL06.01.2021
RO06.01.2021
RS06.01.2021
SI06.01.2021
SK06.01.2021
SM06.01.2021
BG06.04.2021
NO06.04.2021
GR07.04.2021
IS06.05.2021
PT06.05.2021
Former [2023/27]HU12.11.2013
AL06.01.2021
AT06.01.2021
CZ06.01.2021
EE06.01.2021
FI06.01.2021
HR06.01.2021
LT06.01.2021
LV06.01.2021
MC06.01.2021
PL06.01.2021
RO06.01.2021
RS06.01.2021
SI06.01.2021
SK06.01.2021
SM06.01.2021
BG06.04.2021
NO06.04.2021
GR07.04.2021
IS06.05.2021
PT06.05.2021
Former [2022/33]AL06.01.2021
AT06.01.2021
CZ06.01.2021
EE06.01.2021
FI06.01.2021
HR06.01.2021
LT06.01.2021
LV06.01.2021
MC06.01.2021
PL06.01.2021
RO06.01.2021
RS06.01.2021
SI06.01.2021
SK06.01.2021
SM06.01.2021
BG06.04.2021
NO06.04.2021
GR07.04.2021
IS06.05.2021
PT06.05.2021
Former [2022/23]AL06.01.2021
AT06.01.2021
CZ06.01.2021
EE06.01.2021
FI06.01.2021
HR06.01.2021
LT06.01.2021
LV06.01.2021
PL06.01.2021
RO06.01.2021
RS06.01.2021
SI06.01.2021
SK06.01.2021
SM06.01.2021
BG06.04.2021
NO06.04.2021
GR07.04.2021
IS06.05.2021
PT06.05.2021
Former [2022/13]AL06.01.2021
AT06.01.2021
CZ06.01.2021
EE06.01.2021
FI06.01.2021
HR06.01.2021
LT06.01.2021
LV06.01.2021
PL06.01.2021
RO06.01.2021
RS06.01.2021
SI06.01.2021
SK06.01.2021
SM06.01.2021
BG06.04.2021
NO06.04.2021
GR07.04.2021
PT06.05.2021
Former [2022/10]AL06.01.2021
AT06.01.2021
CZ06.01.2021
EE06.01.2021
FI06.01.2021
HR06.01.2021
LT06.01.2021
LV06.01.2021
PL06.01.2021
RO06.01.2021
RS06.01.2021
SK06.01.2021
SM06.01.2021
BG06.04.2021
NO06.04.2021
GR07.04.2021
PT06.05.2021
Former [2022/07]AL06.01.2021
AT06.01.2021
CZ06.01.2021
EE06.01.2021
FI06.01.2021
HR06.01.2021
LT06.01.2021
LV06.01.2021
PL06.01.2021
RO06.01.2021
RS06.01.2021
SK06.01.2021
SM06.01.2021
BG06.04.2021
NO06.04.2021
GR07.04.2021
IS06.05.2021
PT06.05.2021
Former [2021/50]AT06.01.2021
CZ06.01.2021
EE06.01.2021
FI06.01.2021
HR06.01.2021
LT06.01.2021
LV06.01.2021
PL06.01.2021
RO06.01.2021
RS06.01.2021
SK06.01.2021
SM06.01.2021
BG06.04.2021
NO06.04.2021
GR07.04.2021
IS06.05.2021
PT06.05.2021
Former [2021/48]AT06.01.2021
CZ06.01.2021
EE06.01.2021
FI06.01.2021
HR06.01.2021
LT06.01.2021
LV06.01.2021
PL06.01.2021
RS06.01.2021
SM06.01.2021
BG06.04.2021
NO06.04.2021
GR07.04.2021
IS06.05.2021
PT06.05.2021
Former [2021/46]AT06.01.2021
FI06.01.2021
HR06.01.2021
LT06.01.2021
LV06.01.2021
PL06.01.2021
RS06.01.2021
SM06.01.2021
BG06.04.2021
NO06.04.2021
GR07.04.2021
IS06.05.2021
PT06.05.2021
Former [2021/42]AT06.01.2021
FI06.01.2021
HR06.01.2021
LT06.01.2021
LV06.01.2021
PL06.01.2021
RS06.01.2021
BG06.04.2021
NO06.04.2021
GR07.04.2021
IS06.05.2021
PT06.05.2021
Former [2021/39]AT06.01.2021
FI06.01.2021
HR06.01.2021
LT06.01.2021
LV06.01.2021
PL06.01.2021
RS06.01.2021
BG06.04.2021
NO06.04.2021
GR07.04.2021
PT06.05.2021
Former [2021/37]AT06.01.2021
FI06.01.2021
HR06.01.2021
LT06.01.2021
LV06.01.2021
RS06.01.2021
BG06.04.2021
NO06.04.2021
GR07.04.2021
PT06.05.2021
Former [2021/36]FI06.01.2021
HR06.01.2021
LT06.01.2021
BG06.04.2021
NO06.04.2021
GR07.04.2021
PT06.05.2021
Former [2021/35]FI06.01.2021
HR06.01.2021
LT06.01.2021
NO06.04.2021
PT06.05.2021
Former [2021/33]FI06.01.2021
LT06.01.2021
NO06.04.2021
PT06.05.2021
Documents cited:Search[I]WO2007009229  (ANGIOCHEM INC [CA], et al) [I] 1-15 * page 9, line 31 - page 10, line 1; table 2 *;
 [I]WO2008144919  (ANGIOCHEM INC [CA], et al) [I] 1-15 * page 45, line 7 - page 46, line 12; figures 1-7; tables 1,2; sequences 97,107 * * page 50, line 12 - page 54, line 2; figure 16; examples 4,11,12; claim - *;
 [I]US2009016959  (BELIVEAU RICHARD [CA], et al) [I] 1-15 * example -; claims 12,13; table 2 *;
 [I]WO2012000118  (ANGIOCHEM INC [CA], et al) [I] 1-15 * page 68 - page 70; example -; claims 63,69; tables 2,4,5; sequence 97 *;
 [IP]US2013280281  (CASTAIGNE JEAN-PAUL [CA], et al) [IP] 1-15* example -; table - *;
 [I]  - ]!AN E LACHOWICZ ET AL, "Design of new Angiopep-2-anti-EGFR and Angiopep-2-anti-Her2 derivatives with increased blood-brain barrier permeability for treatment of brain tumors", NEURO-ONCOLOGY : OFFICIAL JOURNAL OF THE WORLD FEDERATION OF NEURO-ONCOLOGY, OXFORD : OXFORD UNIV. PRESS, GB, (20120115), vol. 14, no. Suplement, ISSN 1523-5866, pages VI30 - VI31, XP008178859 [I] 1-15 *see abstract number ET-29*
International search[X]WO2010121379  (ANGIOCHEM INC [CA], et al);
 [X]WO2011060206  (U3 PHARMA GMBH [DE], et al);
 [X]  - LACHOWICZ, J.E. ET AL., "Design of new Angiopep-2-anti-EGFR and Angiopep-2-anti-Her2 derivatives with increased blood-brain barrier permeability for treatment of brain tumors", NEURO-ONCOLCOLOGY., WASHINGTON, D.C., (20121015), vol. 14, no. SUPPL, pages VI25 - VI37, XP008178859
 [XP]  - LACHOWICZ, J.E. ET AL., "ANG4043: A new brain-penetrant peptide-antibody conjugate that reduces tumor growth in a HER2-positive orthotopic tumor model. [abstract].", PROCEEDINGS OF THE 104TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, WASHINGTON, DC. PHILADELPHIA (PA), (20130415), vol. 73, no. 8, XP008178860
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.